Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Acute coronary syndromes

STREAMlining care for patients with STEMI

Nature Reviews Cardiology volume 10, pages 304–306 (2013)Cite this article

Subjects

Despite presenting early after symptom onset, some patients with ST-segment elevation myocardial infarction are unable to receive mechanical reperfusion within 60 min. The STREAM trial shows that, among these individuals, fibrinolysis with early angiography is associated with outcomes comparable to modestly delayed primary percutaneous coronary intervention, but with an increased risk of intracranial haemorrhage.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Keeley, E. C., Boura, J. A. & Grines, C. L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361, 13–20 (2003).

    Article  PubMed  Google Scholar 

  2. O'Gara, P. T. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127, e362–e425 (2013).

    PubMed  Google Scholar 

  3. De Luca, G., Suryapranata, H., Ottervanger, J. P. & Antman, E. M. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109, 1223–1225 (2004).

    Article  PubMed  Google Scholar 

  4. Armstrong, P. W. & Boden, W. E. Reperfusion paradox in ST-segment elevation myocardial infarction. Ann. Intern. Med. 155, 389–391 (2011).

    Article  PubMed  Google Scholar 

  5. Armstrong, P. W. et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N. Engl. J. Med. 368, 1379–1387 (2013).

    Article  CAS  PubMed  Google Scholar 

  6. Mathews, R. et al. Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry–Get With The Guidelines. Circulation 124, 154–163 (2011).

    Article  PubMed  Google Scholar 

  7. Bhatt, D. L. Timely PCI for STEMI—still the treatment of choice. N. Engl. J. Med. 368, 1446–1447 (2013).

    Article  CAS  PubMed  Google Scholar 

  8. AHA. Mission Lifeline [online], (2013).

  9. Fosbol, E. L. et al. The impact of a statewide pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary intervention capability on treatment times. Circulation 127, 604–612 (2013).

    Article  PubMed  Google Scholar 

  10. Jollis, J. G. et al. Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state. Circulation 126, 189–195 (2012).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, Duke University Medical Center, Box 3409, 2400 Pratt Street, Durham, 27701, NC, USA

    Akshay Bagai & Christopher B. Granger

Authors
  1. Akshay Bagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher B. Granger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher B. Granger.

Ethics declarations

Competing interests

C. B. Granger has received research support from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic Foundation, Merck & Co., Pfizer, Sanofi-Aventis, Takeda, and The Medicines Company. He has acted as a consultant for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Hoffmann-La Roche, Lilly, Pfizer, Sanofi-Aventis, Takeda, and The Medicines Company. A. Bagai declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bagai, A., Granger, C. STREAMlining care for patients with STEMI. Nat Rev Cardiol 10, 304–306 (2013). https://doi.org/10.1038/nrcardio.2013.62

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2013.62

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing